Cancer BiologybioRxivPreprint
Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination
Noemi Arrighetti, Cesare Soffientini, Valentina Zuco…·Sandro Pasquali
This paper identifies HDAC inhibition as a strategy to overcome resistance to EZH2 inhibitors in INI1-deficient epithelioid sarcoma by restoring H3K27 acetylation and enhancing therapeutic response.